To monitor inflammation in a meaningful way, the markers used must be valid: they must reflect the inflammatory process under study and they must be predictive of future health status. In 2009, the Nutrition and Immunity Task Force of the International Life Sciences Institute, European Branch, organized an expert group to attempt to identify robust and predictive markers, or patterns or clusters of markers, which can be used to assess inflammation in human nutrition studies in the general population. Inflammation is a normal process and there are a number of cells and mediators involved. These markers are involved in, or are produced as a result of, the inflammatory process irrespective of its trigger and its location and are common to all inflammatory situations. Currently, there is no consensus as to which markers of inflammation best represent low-grade inflammation or differentiate between acute and chronic inflammation or between the various phases of inflammatory responses. There are a number of modifying factors that affect the concentration of an inflammatory marker at a given time, including age, diet and body fatness, among others. Measuring the concentration of inflammatory markers in the bloodstream under basal conditions is probably less informative compared with data related to the concentration change in response to a challenge.
A number of inflammatory challenges have been described. However, many of these challenges are poorly standardised. Patterns and clusters may be important as robust biomarkers of inflammation. Therefore, it is likely that a combination of multiple inflammatory markers and integrated readouts based upon kinetic analysis following defined challenges will be the most informative biomarker of inflammation. (1) . (2) . (3) and pro-resolving lipid mediators (4, 5) .
The overall aim of the present study is to attempt to identify robust and predictive markers, or patterns or clusters of markers, which can be used to assess inflammation in human nutrition studies in the general population. Inflammation is a normal component of host defence, initiating the mechanisms involved in pathogen killing and protection against other insults. Thus, in a physiological context, inflammation is protective. Typically, the inflammatory response is activated rapidly in response to infection or another trigger and then follows a temporal pattern of cellular activation and chemical mediator release. Once the infection or the other insult is eliminated, or at least controlled, mechanisms come into play to terminate inflammation in order to limit further damage to the host and to initiate tissue repair. This process is termed resolution of inflammation, and it is now recognised to be an active process involving specific mediators that act to down-regulate the processes that were earlier activated. Failure to resolve inflammation may permit the normally acute inflammatory processes to become chronic. Chronic inflammation may also be driven by continuous exposure to the triggering agent. Chronic inflammation is a well-recognised component of many pathologies and is a target for many pharmacologic interventions. In order to examine the role of diet, foods or specific nutrients on inflammation, it is necessary to identify candidate biomarkers. This review describes a systematic approach to identify generic biomarkers of inflammation and to consider the factors that may influence the status of those biomarkers.

Biomarkers of inflammation
Inflammation: a general overview
Inflammation is a normal host defence mechanism that protects the host from infection and other insults; it initiates pathogen killing, as well as tissue repair processes, and helps to restore homeostasis at infected or damaged sites
A number of different triggers can initiate inflammation. These triggers include the presence of microbial products, tissue damage and metabolic stress (Fig. 1). Exposure to the trigger may involve a breakdown in barrier function or a loss of normal immune tolerance. Irrespective of the nature of the trigger, a common set of cellular pathways is initiated
These pathways include activation of signalling via Toll-like receptors and nuclear factor (NF)-kB, formation of a multiprotein complex termed the inflammasome that is responsible for the release of several inflammatory cytokines, and endoplasmic reticulum (ER) stress (Fig. 1) (2) . The resulting inflammatory response is typified by redness, swelling, heat, pain and loss of function, and involves interactions among many cell types and the production of, and responses to, a vast number of chemical mediators. The precise timing and vigour of the inflammatory response, including the exact cells and mediators involved, is determined by the nature, extent and location of the trigger. These factors act to shape and maintain the inflammatory response. Once the infection or the other trigger is eliminated, or at least controlled, mechanisms come into play to terminate inflammation in order to limit further damage to the host and to initiate tissue repair. This self-regulating process is termed resolution of inflammation and involves the activation of negative feedback mechanisms such as the secretion of anti-inflammatory cytokines, the inhibition of pro-inflammatory signalling cascades, the shedding of receptors for inflammatory mediators and the activation of regulatory cells. Properly controlled inflammation is essential to remain healthy and maintain homeostasis, but inflammation that involves a loss of tolerance or regulatory processes may become pathological (1) . Inflammation may be classified as acute or chronic (Table 1). Acute inflammation is the initial response of the body to an infectious agent or another inflammatory trigger (e.g. tissue damage by wounding or irradiation) and is achieved by the increased movement of plasma and leucocytes (especially granulocytes) from the blood into the site of infection or injury. A cascade of biochemical events matures and propagates the inflammatory response, involving the local vascular system, the immune system and various cells within the injured tissue. Acute inflammation is typically self-limiting with resolution being activated once the cause of the initial response is contained or eliminated. Resolution is itself an active process involving specific cell types and specific anti-inflammatory cytokines
Prolonged, or chronic, inflammation involves a progressive shift in the type of cells present at the site of inflammation and simultaneous destruction and healing of the tissue due to the ongoing inflammatory process. Inflammation may become pathological due to the loss of tolerance and/or of regulatory processes such as resolution. Where this becomes excessive, irreparable damage to host tissues and disease can occur (1) . Such diseases are characterised by markedly elevated concentrations of inflammatory markers and of activated inflammatory cells at the site of tissue damage and in the systemic circulation; this state of inflammation may be regarded as 'high grade'. These diseases include rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), atopic dermatitis, psoriasis and asthma. Chronic inflammation can also be of a 'low grade' and under such circumstances, overt clinical manifestations can be minimal or absent; the elevation in the concentrations of inflammatory markers and of inflammatory cells in the systemic circulation is not as great as that seen in the frank chronic inflammatory conditions described above.
Low-grade asymptomatic inflammation can occur in adipose tissue as a feature of obesity (6) . Under these conditions,
the adipocyte itself becomes the source of inflammationassociated adipokines, although there is also infiltration of adipose tissue by macrophages and T cells, which make important contributions to the inflammatory output from adi-
pose tissue (7) . The cytokines and adipokines released probably contribute to the insulin resistance seen in obesity (8) . Fig. 2 . An overview of inflammation. C, complement; CRP, C-reactive protein; SAA, serum amyloid A; TNFR, TNF receptor; ra, receptor antagonist; PAI, plasminogen activator inhibitor; ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule; CCL, chemokine (C -C motif) ligand; CD62E, E-selectin endothelial leukocyte adhesion molecule 1; CD62P, P-selectin endothelial leukocyte adhesion molecule 1; CXCL, chemokine (C -X-C motif) ligand; tPA, tissue plasminogen activator; vWF, von Willebrand factor; IFN, interferon; PLA, phospholipase A; ROS, reactive oxygen species.
Older people also commonly exhibit low-grade chronic inflammation that may contribute to frailty, depending on the plasma levels of factors such as tumor necrosis factor (TNF) and interleukin (IL)-6. Common to both acute and chronic inflammation is that they have an afferent phase, in which the presence of a trigger is sensed by some types of cells, and an efferent phase, in which an inflammatory response is generated to eliminate the perceived hostile intruder (i.e. the source of the trigger). Irrespective of the type of inflammation, the response involves four major events. The first event is increased blood supply to the site of inflammation. The second event is increased capillary permeability caused by retraction of endothelial cells. This permits larger molecules, not normally capable of traversing the endothelium, to do so and thus delivers some soluble mediators to the site of inflammation. The third event is leucocyte migration from the capillaries into the surrounding tissue (Fig. 2). This is promoted by the release of chemoattractants from the site of inflammation and by the up-regulation of adhesion molecules on the endothelium. Once in the tissue, the leucocytes move to the site of inflammation. The fourth event is the release of mediators from leucocytes at the site of inflammation. These may include lipid mediators (e.g. prostaglandins (PG), leukotrienes; see
conditions that have an inflammatory component and altered nutrition may be useful in the prevention or treatment of such conditions (1, 6) . (13) . (13) . The overall aim of this review is to identify robust and predictive markers, or patterns or clusters of markers, that can be used to assess inflammation in human nutrition studies in the general population and to create a consensus for grading these biomarkers.
How were the biomarkers chosen?
In order to select likely biomarkers of relevance to nutrition studies, it was decided to first identify general and diseasespecific markers of inflammation within the circulation (Table 6 ). Tables 5 and 6 ). These modifiers should all be considered when designing a study aimed at measuring inflammatory biomarkers. Th, helper T; IFN, interferon; VEGF, vascular endothelial growth factor; CXCL, chemokine (C-X -C motif) ligand; GRP, glucose-related protein; PKR, protein kinase R; SMAD, Intracellular proteins that transduce extracellular signals from TGF beta ligands; CPN, chaperone; MAPK, mitogen-activated protein kinase; LT, leukotriene; CRP, C-reactive protein; SAA, serum amyloid A; ra, receptor antagonist; R, receptor; CCL, chemokine (C -C motif) ligand; vWF, von Willebrand factor; VCAM, vascular cell adhesion molecule; ICAM, intercellular adhesion molecule; PAI, plasminogen activator inhibitor; sPLA 2 , soluble phospholipase A 2 ; C, complement. response is associated with enhanced survival (14) . (15) . Several studies have reported ageassociated increases in total leucocyte numbers (16, 17) and in soluble concentrations of soluble pro-inflammatory cytokines such as IL-1 (18, 19) , IL-6 (14, 18, 20, 21) and TNF (22, 23) , although this has not been seen in all studies (21, 24) . Others have reported higher concentrations of IL-1 receptor antagonist (14, 21, 25) and of TNF-receptors (24, 25) with increased age. In line with these findings, many studies have reported higher concentrations of downstream markers such as acute-phase proteins like CRP (14, 26) , a1-acid glycoprotein (27) and fibrinogen (14, 20, 28) . (30) . Similarly, there is some evidence that con-
Key messages (1) Acute inflammation is a normal physiological response critical to maintain homeostatic control, but when it becomes chronic, inflammation contributes to the pathophysiology of a range of diseases. (2) Common soluble markers of inflammation include cytokines, chemokines, lipids, acute-phase proteins and adhesion molecules. (3) Common blood cellular markers of inflammation include various subclasses of leucocytes. The same markers are involved in both acute and chronic inflammatory processes, meaning that the markers themselves, in isolation, cannot be used to distinguish the two processes.
Modifiers of inflammatory markers
Influence of age
A certain degree of inflammation may be part of adaptability and homeostasis in older people, and it has been demonstrated that their ability to mount a vigorous inflammatory
ecules (VCAM-1, ICAM-1, E-selec- tin, P-selectin), PAI-1, low adipo- nectin CRP, SAA, fibrino- gen, cytokines (TNF, IL-1, IL-1ra, IL-6, IL-8, TNFR), chemokines (CCL2), vWF, adhesion mol- ecules (VCAM-1, ICAM-1, E-selec- tion, P-selectin), PAI-1, a-1-anti- trypsin,
Fewer studies have addressed the relationship of ageing with chemokines and adhesion molecules, although in some studies, vascular cell adhesion molecule (VCAM)-1 (29,30) and intercellular adhesion molecule (ICAM)-1 (30) have been shown to have higher concentrations in older persons while E-selectin was not
, plasminogen activation inhibitor-1 (32) and adiponectin (33, 34) (38) . Inflammatory markers in older persons may also be influenced by co-morbidity, medication use or malnutrition (39 -43) . However, there are some indications that once co-morbidities are accounted for, inflammation is still associated with ageing (14, 15) . 
Influence of body fatness and fat distribution
As stated earlier, white adipose tissue secretes cytokines and chemokines, and macrophage and T-cell infiltration is dramatically increased in the adipose tissue of obese humans (51) . Obesity is associated with a state of low-grade chronic inflammation. Total blood leucocyte numbers are positively associated with obesity and the metabolic syndrome (16,17,52 -54) . Differential leucocyte counts indicate that neutrophils, but not monocytes or lymphocytes, account for this predictive potential (17) . There are higher concentrations (79) . Furthermore, other adipose tissue depots in so-called 'ectopic sites', such as within the liver, heart or skeletal muscle, may contribute to the production of inflammatory mediators even in the absence of obesity (80) . In this regard, the local production of inflammatory molecules by adipose tissue within the heart may be important; the amount of this tissue and its proximity to the coronary vessels could contribute to the development of coronary pathologies (81, 82) . Although there has been considerable focus on the role of low-grade chronic inflammation in overweight, obesity and the metabolic syndrome (6) , it is important to recognise that underweight also appears to be associated with low-grade chronic inflammation. For example, adolescent anorexia is associated with elevated levels of some inflammatory cytokines including TNF-a (83) , and low-grade chronic inflammation is associated with low body weight in older subjects (84) . Several proinflammatory cytokines, most notably TNF-a, have a causal role in cachexia (85) .
Influence of physical (in)activity
Physical (in)activity resulting in inadequate energy expenditure relative to intake may lead to the accumulation of visceral fat and consequently to the activation of inflammatory processes associated with this (86) . In contrast, physical activity promotes health and this may relate to the anti-inflammatory effect of regular exercise, which reduces visceral fat mass and induces an anti-inflammatory environment (87, 88) . Subjects engaged in regular physical activity have lower blood leucocyte numbers (89) . Plasma concentrations of IL-6 are lower in individuals who undertake regular physical activity than in those who do not (90) . The lower concentrations of IL-6 in the circulation will subsequently result in lower CRP levels. Several studies of large population cohorts have provided evidence for an inverse, independent doseresponse relationship between the level of habitual physical activity and plasma CRP concentration in both men and women (91 -96) . Moreover, CRP levels in 2120 Finnish participants were associated with obesity indices (positively) and physical activity (inversely) among both sexes (97) . Cross-sectional studies have demonstrated that cardiorespiratory fitness levels are inversely associated with CRP concentrations and also the prevalence of elevated CRP concentrations (98) . (99 -106) . (116 -119) . Thus, genotype can influence the plasma concentration of inflammatory markers (116, 120, 121) . (122, 123) , infectious disease (123, 124) and cancer (123, 125) .
However, conflicting findings exist and several training interventions have not produced changes in basal IL-6 or CRP levels
Ethnicity is related to genetic variation. (127) . The differences among groups were retained after adjusting for age and BMI. (136) . Some adhesion molecules are also increased in the serum of smokers compared with non-smokers, including ICAM-1, P-selectin and E-selectin (130, 141) . (157, 158) . This suggests that there is potential for treating IBD through microbiota manipulation and modifications of interactions with the gut immune system. These findings provide a rationale for microbial characterisation in many other inflammatory diseases, such as psoriasis and allergic asthma. As in IBD, specific alterations of skin and airway microbiota are observed in patients with inflammatory diseases manifested at these sites (159 -164) . More recently, gut microbiota in atopic dermatitis and in obese people has also been carefully addressed and a specific profile was found, indicating that gut commensals may also exert remote effects (145, 165, 166) . However, the precise causal role and the mechanisms involved remain to be established. (167, 168) . (169, 170) . (171) . These changes affect the metabolic potential of the gut microbiota and support an increased capacity to harvest energy from the diet in obese people (172 -174) . These features of obesity are transmissible as faecal material transfer from obese human adults to germ-free mice resulted in higher total body fat accumulation over time in contrast to lean human adult faecal material transfer (172 -174) .
Influence of smoking
Recent findings have also suggested that gut microbiota is a factor in metabolic diseases, as reviewed recently
The same specific gut microbiota alterations have also been reported in obese v. lean human subjects (reduced global diversity and relative increase in the ratio of Bacteroidetes:Firmicutes). F. prausnitzii was reduced in obese diabetic subjects compared with lean controls and was negatively correlated with serum levels of circulating inflammatory markers such as CRP and IL-6 in these subjects
Influence of diet
The influence of diet on soluble markers of inflammation in different contexts has been described in detail elsewhere (1, 6) and will not be considered further here.
Influence of medication
It is obvious that whether specific or non-specific to particular disease processes and pathways or to a particular disease, pharmacologic treatment of inflammation is bound to greatly influence biomarker levels. A classic example is the influence of corticosteroids in autoimmune, allergic or mucosal inflammatory conditions; corticosteroids are powerful modifiers of cytokines and growth factors that influence other biomarkers such as CRP levels in RA and eosinophil levels in asthma. Indeed, such biomarkers are valuable in monitoring therapeutic responses and adherence to treatment. Selective treatments such as targeted biologics (e.g. anti-TNF therapy in inflammatory joint and bowel diseases) can also influence biomarkers and, again, these may be used to monitor therapy. It is, therefore, of utmost importance when using biomarkers for clinical decision making that any concurrent therapy that may influence their level or expression is taken into account.
Influence of other modifiers
In addition to the modifiers already considered, inflammatory biomarkers may be influenced by emotional stress (175 -177) , exposure to pollution (178) and sleep behaviour (179) among other factors. (Fig. 3) 
Summary
Among non-diseased individuals, the concentrations of the soluble markers and the numbers of some of the cellular markers of inflammation are altered with increasing age, body fatness and physical (in)activity, and are modified by genetics, smoking status, gut microbiota and medication use among other factors
Challenge models
Why challenge models are relevant (182, 183) , (185 -190) . (190) . (57, 192) and are sensitive to modulation by pharmaceutical, lifestyle and dietary interventions (185 -190,193) . The (Fig. 4 ) (194 -198) . (199) , but could also be detected after 1 or 2 d (200, 201) or even after several weeks (202) . In contrast, no change in IL-6 2 weeks after vaccination was noted by Glaser et al. (203) . TNF was not increased 3 h after vaccination in a single study (204) , and CRP was increased in three vaccination studies (200, 201, 205) . Other markers that have been described to increase after vaccination are MCP-1, eotaxin and IL-13 (206) , as well as IL-2, IL-12 and IL-15 (207) . (199 -207) . High (type and dose of trigger, subjects, time points, markers) CRP, C-reactive protein; T2D, type 2 diabetes; LPS, lipopolysaccharide; CCL, chemokine (C-C motif) ligand; DTH, delayed-type hypersensitivity; ", positive association; #, negative association; $, no clear association. * Times indicated in parentheses are the approximate times of the maximal plasma concentration of the marker.
The forgoing discussion has focused on individual markers of inflammation typically measured in the blood of individuals in the resting (e.g. fasting) state. Such measurements may differentiate between those individuals with an overt inflammatory disease and those without, and may also indicate the effects of influencing factors such as age, body fatness, physical (in)activity, genetics, smoking habit and the composition of the gut microbiota on chronic inflammatory tone. However, such measurements provide little information about an individual's (acute) inflammatory response to a challenge. It has been suggested that dynamic responses to challenges provide a more sensitive and meaningful indication of health (180,181) . More specifically, the dynamic inflammatory responses to a physiological challenge may provide a better (more relevant, sensitive, better interpretable) indicator of the impact of nutrition on inflammatory homeostasis and thus on the control of (acute) inflammatory responsiveness. Currently, relatively little is known about inflammatory markers after wellcontrolled acute challenges and whether these can be used to assess the effect of nutritional interventions on acute and/ or chronic inflammation. It is also not known what exactly constitutes an optimal inflammatory response to a challenge. This will need to be established by comparing standardised responses with challenges in different (sub)populations and by exploring their predictive value in prospective cohort studies. Despite these current gaps in knowledge, assessment of inflammatory resilience after experimental pro-inflammatory challenges is increasingly being studied. This section describes the inflammatory challenges that have been used to date and makes conclusions about their utility with regard to human studies involving nutritional interventions. A range of challenges that induce an acute inflammation was identified from the literature (Table 7). These challenges can be clustered according to the dominant stress triggering the inflammatory response: metabolic stress or metabolic overload (oral glucose load and oral lipid load); infection stress (injection of pro-inflammatory stimuli such as lipopolysaccharide (LPS), TNF or IL-6; early response to (adjuvants in) vaccines
but 75 g (1255 kJ (300 kcal)) of glucose are typically given as a standardised drink in accordance with the recommendations of the World Health Organization (WHO) (184) . The oral glucose load induces a transient inflammatory response, which has been assessed in several studies as levels of circulating cytokines. Levels of CRP and IL-6 consistently increase, peaking after 1 and 2 -4 h, respectively
Responses of TNF seem to be more variable. Several studies have described increases in markers of vascular inflammation such as ICAM-1 (191) , VCAM-1 and E-selectin, peaking about 2 h (186) . Most markers normalise 3 -4 h after the OGTT, but responses tend to be extended and/or stronger in obese, insulin-insensitive and type 2 diabetic patients
Oral fat challenge. Testing responsiveness to an oral challenge with fat is sometimes referred to as the oral fat tolerance test. However, unlike the test (OFTT), this is not an established diagnostic test with a standardised WHO-recommended protocol. Quality (fatty acid composition) and quantity of the fat have differed between studies. The fat is provided as a bolus (e.g. 200-350 ml whipping cream) in some studies, whereas it is provided as a high-fat meal in other studies (e.g. 50 -75 g fat as part of a meal). Most studies have focused on the effects of the OFTT on fatty acid handling, but the effects on markers of (vascular) inflammation have also been described. Postprandial lipaemia as induced by the OFTT is associated with a transient increase in markers of (vascular) inflammation, but the size and kinetics of these responses are quite variable between studies, undoubtedly due in part to the different protocols used. It has been suggested that the responses differ between healthy individuals and the obese as well as those with type 2 diabetes
These findings have indicated that pro-inflammatory cytokine levels can be measured after vaccination; however, more studies are needed to standardise a vaccination approach as an inflammatory challenge. Feasibility is expected to be high, and the responses noted seem quite reproducible, suggesting that most persons tested will indeed respond by the production of pro-inflammatory mediators. Using vaccination as an inflammatory challenge could be relevant to identify anti-inflammatory effects of nutritional intervention. An added advantage is that protective
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British Journal of Nutrition (208) . (209 -211) . (212) . To control both the sensitisation and elicitation phase, studies have also explored the use of experimental sensitisation to an uncommon contact sensitiser, diphenylcyclopropenone, that would not normally be encountered (213, 214) . Although there are ethical considerations, this has been successfully used to assess the effect of (exercise) intervention on both the sensitisation and elicitation phase using induration due to the local inflammation of the skin as the readout (215) . (216) . (87, 88) . Increases in such inflammatory cytokines after short-term exercise are much less pronounced. The production of IL-6 increased after mild exercise in studies performed in healthy as well as diseased adults (217 -221) , but was unchanged in other studies (222, 223) . . (220, 222, 224) and increased in another study (218) . The numbers of circulating total leucocytes, lymphocytes and monocytes increased after mild exercise (225) . Interestingly, in some studies, inflammatory cytokines increased after moderate exercise in patients, but not in control subjects. Rabinovich et al. (223) described that serum TNF increased in patients with cystic fibrosis after moderate exercise but not in controls. Likewise, IL-6 increased after mild exercise in cystic fibrosis patients, but not in healthy controls in another study (224) . The effect of mild exercise on CRP was only tested in a single study, and was found to be increased in patients with coronary artery disease but not in control subjects (219) . Similar findings have been seen in studies with children (226) . UV irradiation. Whole-body exposure to high doses of sunlight or UVB radiation causing sunburn increases the levels of inflammatory mediators in the circulation. Milder or more focused exposure to UVB radiation was shown to decrease the skin contact hypersensitivity response (214) as well as some systemic responses such as natural killer cell activity (214, 227) and ex vivo production of cytokines (228) . However, circulating cytokine levels after single exposure to UVB were not affected (229, 230) and even after 10 d of repeated exposure, only IL-8 and TNF were marginally increased (230) . It is therefore unlikely that a practically feasible UV challenge There is an initial appearance of inflammatory cytokines (TNF and IL-1), followed by IL-6, and then anti-inflammatory cytokines (TNF receptor (TNFR), IL-1 receptor antagonist (IL-1ra) and IL-10). Reproduced from Bentham Science Publishers (300) with permission.
Whereas muscles produce the pro-inflammatory IL-6 during acute bouts of exercise; paradoxically, IL-6 also has anti-inflammatory effects by promoting the release of IL-1 receptor antagonist and
This may in part explain the notion that regular, mild, lowimpact exercise has anti-inflammatory effects. The production of TNF remained unchanged after mild exercise in healthy as well as diseased adults in three studies
can be developed that can be used to assess indicators of inflammation systemically. However, using microdialysis and/or punch biopsies, pro-and anti-inflammatory responses can be sequentially assessed in the skin in the hours to days following a single dose of two or three minimal erythemal doses of UVB radiation (231 -233) . This is a useful model to assess local mediators including short-lived eicosanoids involved in the initiation and resolution phase of UVB-induced skin inflammation (234) .
General comments on challenge models 
Clusters of markers
An important approach to ascertaining the clinical relevance of selected biomarkers of inflammation is to perform longitudinal studies following human subjects over time (241) . (244, 245) . (1, 6) , it is likely that the clusters themselves may be targets for nutritional interventions.
Stress markers
The adverse tissue environment of immune-mediated and metabolic disease triggers a cellular stress programme in response to hypoxia, inflammation, reactive oxygen species as well as the lack or imbalanced presence of nutrients (246) .
Specific metabolic and functional processes occur in specialised cellular organelles such as the ER, peroxisomes and mitochondria (247) . The unfolded protein response (UPR) is a well-conserved mechanism of these organelles to restore cellular homeostasis in response to stress; however, unresolved or chronic activation of UPR pathways induces inflammatory mechanisms or cell death. Even though they are phenotypically different, the diseases described in Table 4 share similarities of the cell stress response at the molecular level (248) . (257) . In addition, plasma HSP60 levels were associated with hypertension and increased risk for CVD (258, 259) . (261) . Endogenous circulating miRNA in human plasma are potential candidates as stable biomarkers for health status, organ dysfunction and disease (262 -264) . As many of the common diseases have an inflammatory component that may be regulated by non-coding RNA (265) , it is expected that plasma miRNA profiling will reveal sensitive biomarkers for the onset or modulation of chronic inflammation in humans (262,266 -268) . The latter could include nutritional modulation. (269, 270) . (269) . The usefulness of such tools in the generally healthy population needs further development. In addition, specific bacterial 16S ribosomal DNA detection by PCR amplification in blood is a tool being used more frequently (271 -273) . (274) . The 16S
Microbiota and associated markers
ribosomal DNA concentration was analysed in blood in a cohort of 3280 subjects without diabetes or obesity. Baseline 16S ribosomal DNA level was higher in those subjects who developed diabetes by the 9-year follow-up (274) .
Key messages 
Emerging technologies
Applications of omic technologies to identify new markers and to monitor the effect of interventions (276 -280) . (279, 281) . (282, 283) . (284 -286) . Recent studies have already shown the great opportunities of this new research area (191, 287, 288 (289) . Pathway analyses revealed significantly decreased expression of genes involved in inflammatory pathways, such as eicosanoid synthesis, cytokine signalling and mitogen-activated protein kinase signalling, and in pathways related to atherosclerotic processes, such as cell adhesion and scavenger receptor activity (289) (290) . (291) . (291, 292) (181, 235, 293) .
It is becoming evident from recent studies that nutrigenomics is promoting an increased understanding of how a nutritional intervention mechanistically influences
Non-invasive imaging
Recent developments in non-invasive molecular imaging (such as magnetic resonance imaging) are allowing quantification of physiological changes in vivo using specific probes. Nanoprobes can be used to image specific cells and tissues within a whole organism, at the moment mainly in animal models such as mice (294) . Intravital fluorescence microscopy in mice is beginning to provide quantitative and dynamic insights into cell biology and immunology (295) .
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British Journal of Nutrition Recent application of specific mass spectrometry techniques in combination with magnetic resonance imaging has provided a systems biology approach to study inflammation in mice (296) . (297) . Finally, non-invasive imaging has been applied in mouse models of inflammatory disease and for imaging of macrophages in vivo by using activatable fluorescent probes, radiolabelled inhibitors and nanoparticles (298) . Increasingly, these imaging techniques are also discussed for their potential to identify subclinical atherosclerosis in humans (299) . 
